What happened
Jeil Pharmaceutical reported consolidated results for FY2025: revenue of US$392M (−19.6% year on year), operating profit of US$14.3M (from a loss a year earlier) and net income of US$22.2M (from a loss a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$392M |
|---|---|
| Revenue vs a year earlier | −19.6% |
| Operating profit | US$14.3M |
| Net income | US$22.2M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-23, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260223801388 → open original filing |
Source: DART. Information only, not investment advice.